Abstract: For the pharmacological treatment of frequency, urgency and/or urge incontinence due to bladder overactivity, anticholinergics have been used as first-choice drugs. However, these drugs can exert severe side effects (accommodation paralysis, constipation, tachycardia, dry mouth and blurred vision) and some patients are refractory to their actions. Thus there is a need for new drug therapies with novel mechanisms of action.
INTRODUCTION
For the pharmacological treatment of frequency, urgency and/or urge incontinence due to bladder overactivity, anticholinergics have been the treatment of choice. However, these drugs can exert severe side effects (accommodation paralysis, constipation, tachycardia, dryness of mouth and blurred vision) and some patients are refractory to their actions. Thus there is an urgent need for new drug therapies with novel mechanisms of action [1] .
-Adrenoceptors have been demonstrated in the bladder and urethra of several species including human where they mediate relaxation [2] [3] [4] [5] . -adrenoceptor subtypes, members of the GTP-binding protein (G-protein)-coupled receptor family with seven-transmembrane regions, are classified intourge incontinence [15, 16] , these drugs have not been used because of the limited therapeutic effects [17] . Recently, 3 adrenoceptors have been reported to be predominantly present in the human bladder [18] [19] [20] . 3 -Adrenoceptors have also been reported to predominantly mediate relaxation of the human bladder smooth muscle [18, 19, 21] . However, their efficacies for the treatment of urge incontinence remains to be determined. In this review, we have compared the effects of -adrenoceptor subtypes on relaxation of smooth muscles of the lower urinary tract.
MECHANISMS OF -ADRENOCEPTORS FOR RE-LAXATION OF THE URINARY BLADDER SMOOTH MUSCLE
The activation of -adrenoceptors has been shown to relax bladder smooth muscle in many species including humans. The -adrenoceptor is a Gs-protein-coupled receptor. The activation of -adrenoceptors stimulates adenylyl cyclase to increase cyclic AMP level, which activate protein kinase A to express its biological effects [22] . Nakahira et al. [23] reported that isoproterenol prevented spontaneous action potentials and increase in transient intracellular Ca
2+
, and that this drug activated protein kinase A to hyperpolarize the cell membrane, probably through activation of sodium pump activity. Stimulation of -adrenoceptors has been reported to exert negative modulation of L-type Ca 2+ channels via cAMP/protein kinase A-dependent mechanism [24] . It has also been reported that isoproterenol-induced relaxation of guinea pig bladder was mainly mediated by facilitation of large-conductance Ca 2+ -activated potassium (BK Ca ) channels subsequent to the activation of the cAMP/protein kinase A pathway [25, 26] . However, Nakahira et al. [23] reported that various potassium channel blockers had no effect on isoproterenol-induced hyperpolarization.
In addition to the direct relation of smooth muscle of the bladder, -adrenoceptor stimulation has been reported to activate the adelylyl cyclase pathway in the epithelial cells of the rat bladder and initiate an increase in intracellular Ca 2+ that triggers NO production and release [27] .
WHICH MUSCARINIC RECEPTOR SUBTYPES ARE PRESENT IN THE URINARY BLADDER? (TABLE 1)
It has been reported that -adrenoceptors are predominantly located in the bladder dome rather than in the bladder base or urethra [4, 28, 29] . Previously, Levin et al. [4] have demonstrated a predominance of 2 -adrenoceptors using radioligand binding studies in human detrusor smooth muscle, and Goepel et al. [30] have reported that 2-adrenoceptors predominate in the pig and human detrusor. Guinea pig bladder has been reported to contain 1 -and 2 -adrenoceptors [5] .
Yamanishi et al. [28, 29, 31] reported that, in radioligand binding studies using [ 3 H]DHA and displacement with selective 2 -and 3 -adrenoceptor antagonists (ICI 118551 and SR59230A, respectively), 3 -adrenoceptors were predominantly present in the bladder dome, bladder trigone and urethral smooth muscle of the pig, the 2 -: 3 -adrenoceptors being approximately 1:3. However, 1 -adrenoceptors were not present in the pig bladder. Expression of mRNA encoding for the 3 -adrenoceptors as well as 1 -and 2 -adrenoceptors has been found in the bladders of rat [32] and human [18, 19, 33] . Recently, Nomiya and Yamaguchi [20] reported that, in a real-time quantitative reverse transcriptase-polymerase chain reaction, the mRNA of 1 -and 2 -adrenoceptors was expressed at low levels, while 3 -adrenoceptors was the most highly expressed subtype in both normal and obstructed bladders, accounting for 94.4% and 95.7%, respectively, of the overall 1 and -adrenoceptors.
FUNCTIONAL ROLE OF -ADRENOCEPTOR SUB-TYPES FOR RELAXATION OF THE URINARY BLADDER (TABLE 1)
Although 3 -adrenoceptors have been found to be predominantly present in the bladders of pig and human [18, 19, 28, 29] , it does not always mean that 3 -adrenoceptors predominantly mediate relaxation of the bladder. For example, M 2 muscarinic receptors are predominantly present in the bladder but it is the minor population of M 3 muscarinic receptors that mainly mediate contraction of the bladder smooth muscle [34] .
The -adrenoceptor subtype mediating relaxation appears to be species dependent. Previously (before the 3 -adrenoceptor was identified), the predominant -adrenoceptor subtype mediating relaxation of the bladder smooth muscle had been reported to be 1 -adrenoceptor in the cat and guinea pig [5, 35] and the 2 -adrenoceptor in the rat, rabbit and human [4, 36, 37] . However, Nergårdh et al. [35] and Larsen [38] have reported that relaxation of the human bladder is blocked by propranolol but not by practolol ( 1 -adrenoceptor antagonist) or butoxamine ( 2 -adrenoceptor antagonist), suggesting the presence and functional characteristics of non 1 -, non 2 -adrenoceptors. Recently, role of 3 -adrenoceptor subtype has been studied in various animals and human using 3 -adrenoceptor selective agonists and antagonists. In the rat bladder smooth muscle, the -adrenoceptor mediated relaxation has been reported to be via 2 -and 3 -adrenoceptors [10, 39, 40] . In cynomolgus monkey, 3 -adrenoceptor solely mediates relaxation [41] . Yamazaki et al. [42] have reported that relaxation of the bladder smooth muscle is mediated mainly via 2 -adrenoceptor in rabbits, both 2 -and 3 -adrenoceptors in rats, and 3 -adrenoceptor in dogs. The 3 -adrenoceptor agonist, CL 316243, has also been reported to be effective in inhibiting contraction of the rat bladder in the normal and overactive state both in vitro and in vivo [43, 44] . Takeda et [20] al. [44, 45] suggested that 3 -adrenoceptor agonists may have a potential role in treating overactive bladder without causing cardiovascular side effects because only a low level of 3 -adrenoceptor is present in the human heart, and 3 -adrenoceptor agonists had only a slight influence on blood pressure and heart rate in the rat. Another 3 -adrenoceptor agonist, 138-355 (an active-metabolite of TT-138 and free compound of GS-332), has also been reported to relax bladder smooth muscle of the rat [46] . Yono et al. [47] reported that isoproterenol and procaterol ( 2 -adrenoceptor agonist) significantly relaxed rabbit bladder, but that relaxation response to GS332 ( 3 -adrenoceptor agonist) and dobutamine ( 1 -adrenoceptor agonist) was small. However, estrogen treatment caused increased relaxant responses to isoproterenol, procaterol and GS332. On the other hand, Matsubara et al. [48] reported that 3 -adrenoceptor agonists relaxed more in ovariectomized rat urinary bladder than in ovariectomized rats with estrogen replacement or in control rats, suggesting greater relaxant effects of 3 -agonists in the female rats with low estrogen levels. Kubota et al. [49] reported that, in the rat bladder with experimental diabetes induced by streptozotocin, relaxant responses to isoproterenol were greater than control, and those to T-0509 (a 1 -adrenoceptor agonist) were augmented by diabetes.
Yamanishi et al. [28] reported that, in pig bladder, (±)salbutamol ( 2 -adrenoceptor agonist) induced relaxation with a high potency (pEC50 value of 7.2) and with a mean maximum relaxation of 86 % of that obtained to 30 M (±)isoproterenol. However the 3 -adrenoceptor agonists CGP12177 and BRL37344 had a lower potency (pEC 50 =4.0 and 6.9, respectively), and with maximum relaxation responses of 40 % and 59%, respectively, of that to 30 M isoproterenol. They also reported that both the 2 -antagonist (ICI118551) and the 3 -antagonist (SR59230A) antagonised responses to isoproterenol with a relatively high affinity, but with the Schild slope less than unity, suggesting that responses were mediated by both 2 -and 3 -adrenoceptors. However, 1 -adrenoceptors were not involved in pig bladder. In smooth muscles of pig bladder trigone, -adrenoceptor mediated responses to isoproterenol and salbutamol are mediated via both the 2 -and 3 -adrenoceptor subtypes [31] .
In human bladder, Igawa et al. [18, 50] reported that neither (±)dobutamine ( 1 -and 2 -adrenoceptor agonist) nor procaterol ( 2 -adrenoceptor agonist) produced any significant relaxation, but that BRL 37344 and CGP 12177A ( 3 -adrenoceptor agonists) induced relaxation with mean pEC 50 values of 6.4 and 5.7, respectively. However, the maximum relaxations induced by these 3 -adrenoceptor agonists were only half of that produced by (±)isoproterenol. They have also reported that, in the presence of CGP 20712A and ICI 118551 ( 1 -and 2 -adrenoceptor agonists, respectively), SR58894A ( 3 -adrenoceptor antagonist) antagonised isoproterenol-induced relaxation curves, but with a low affinity (pA 2 value of 6.2) and produced a Schild plot with a low slope (0.68) [18] . The pA 2 value of 6.2 obtained by these authors for SR58894A is close to that obtained on the guinea -pig trachea ( 2 -adrenoceptors) and less than that obtained at the 3 -adrenoceptors of the rat proximal colon (pA 2 value of 8.1) [51] . Takeda et al. [19] have reported that BRL37344 and CGP12177A exhibited relaxant effects in human detrusor smooth muscle with pD 2 (pEC 50 ) values of 6.3 and 5.9, respectively, and intrinsic activity values relative to isoproterenol of 0.48 and 0.50, respectively. However they have reported that ZD-7144, another putative 3 -adrenoceptor agonist, elicited only a slight effect (intrinsic activity value relative to isoproterenol being 0.09). Nomiya and Yamaguchi et al. [20] reported that isoproterenol and L755,507 ( 3 -agonist) produced concentration-dependent contraction in bladder strips with patients with normal and obstructed bladder condition. However, the relaxing effects of dobutamine ( 1 -and 2 -agonist) and (±)clenbuterol ( 2 -agonist) were observed only at a high dose (10 -4 M). Yamanishi et al. [52] also reported that involvement of the 3 -adrenoceptor was greater than that of the 2 -adrenoceptor for relaxations of the human bladder, and that the relaxation response of 138-355, a 3 -adreno-ceptor agonist, was mediated via the 3 -adrenoceptor stimulation. These results suggested that the relaxation induced by -adrenergic stimulation of the human bladder was mainly mediated via 3 -adrenoceptors, but also suggested the involvement of other -adrenoceptor subtypes.
2 -Adrenoceptor subtypes have also been reported to play a role in relaxation of the detrusor muscles. Hudman et al. [53, 54] reported that clenbuterol, a 2 -adrenoceptor agonist, inhibited rat detrusor muscle contraction in response to electrical field stimulation and ATP stimulation, but not to carbachol, and that clenbuterol resulted in the activation of K ATP channels with subsequent relaxation via the activation of protein kinase A. They also reported that oral administration of clenbuterol inhibited contractile responses of human detrusor muscle strips from patients with detrusor overactivity but not in muscle strips from continent patients [55] . Clinically, some studies reported the efficacies of 2 -adrenoceptor agonists in the treatment of urge incontinence [15, 16] , but others reported the limited therapeutic effects [17] .
Another possibility is heterogeneity of 3 -adrenoceptors or other -adrenoceptors, possibly 4 -adrenoceptor and/or atypical -adrenoceptors, may coexist and play a functional role in mediating the relaxation of the human bladder [8, 10, 18] . Longhurst & Levendusky [10] have reported that BRL 37344 relaxed rat urinary bladder with high potency, but SR 58611A, another 3 -adrenoceptor agonist was less potent. They have speculated the existence of atypicaladrenoceptors in rat bladder, in addition to the 3 -adrenoceptor subtype. In addition, most of drugs used in the above studies are racemic mixtures and the stereochemistry of the drugs should be considered.
In conclusion, 3 -adrenoceptors may have a major role in -adrenoceptor mediated relaxation of the human bladder, but the role of 2 -adrenoceptors or other -adrenoceptor subtypes cannot be excluded (Fig. 1) .
THE FUNCTIONAL ROLE OF -ADRENOCEPTOR SUBTYPES IN THE URETHRA
It has been reported that -adrenoceptors are predominantly located in the bladder dome rather than in the bladder base or urethra. -Adrenoceptor density in the dome was almost 3-fold greater than that observed in the bladder base or proximal urethra of the dog, rabbit and pig [29, 56] . Al-though urethral smooth muscle contraction is predominantly mediated via -adrenoceptor closing the urethra during bladder filling, it is also relaxed via -adrenoceptor stimulation [57] [58] [59] [60] . Vaidyanathan et al. [57] reported that subcutaneous injection of (±)terbutaline, a 2 -adrenoceptor agonist, demonstrated a decrease in maximum urethral closure pressure in patients with neurogenic bladder dysfunction. It has been reported that the activation of cAMP throughadrenoceptors cause relaxation of the smooth muscle of the pig bladder and urethra, and that M 2 -muscarinic receptor subtypes inhibit this relaxation [34] .
Yamanishi et al. [61] reported that, isoproterenol and BRL37344 relaxed pig urethral smooth muscle with high potency (pEC 50 =7.2 and 8.1, respectively), whilst (±)salbutamol ( 2 -adrenoceptor agonist) had low potency (pEC 50 =6.1). Mean % maximal relaxation responses of BRL37344 and salbutamol relative to the 30 M isoproterenol responses were 89.8% and 76.7 %, respectively. From the antagonist affinities of propranolol ( 1 -and 2 -antagonist), ICI118551 ( 2 -antagonist) and SR59230A ( 3 -antagonist) against responses to isoproterenol, (±)salbutamol and BRL 37344, it was suggested that 3 -adrenoceptor predominantly mediated relaxation, and 2 -adrenoceptor also had a contribution to relaxation in the pig urethra. On the contrary, Takeda et al. [62] reported that the relaxant effects of -adrenoceptor agonists on the urethra of the dog and rat were mainly mediated via 2 -adrenoceptors in vitro and in vivo (Fig. 1) .
Thus -adrenoceptor agonist or -adrenoceptor antagonist has been considered to be effective for the treatment of stress incontinence, by enhancing the contractility of smooth muscle of the urethra. Although propranolol, a -adrenoceptor antagonist, has been reported to be effective in the treatment of stress incontinence [63] , its effect has not been proven by controlled studies. On the contrary, (±)clenbuterol, a 2 -adrenoceptor agonist has been reported to enhance the contractility of the fast-contracting (type 2) fibres of the urethral striated muscles, and thus to be effective in the treatment of stress incontinence [21, 64, 65] . It has also been reported that clenbuterol induce marked relaxations in the rat, rabbit and human bladder smooth muscles and also induced marked contractions in the rat periurethral striated muscles, while GS332, a 3 -adrenoceptor antagonist, induced marked relaxations in the rat and human bladder and small contractions in the rat periurethral striated muscles (Fig. 1) [21] . Consequently, it has been speculated that 3 -adrenoceptor agonist is effective for the treatment of detrusor overactivity and 2 -adrenoceptor agonist is effective for stress incontinence [61] .
CONCLUSIONS
Both 2 -and 3 -adrenoceptors are present in urinary bladder of the pig and human with the 3 -adrenoceptor subtype predominating. Functionally, 3 -adrenoceptors may have a major role in -adrenoceptor mediated relaxation of the human bladder, but the role of 2 -adrenoceptors or other -adrenoceptor subtypes (atypical or 4 -adrenoceptors) cannot be excluded. Consequently, 3 -adrenoceptor may be a potential target for the new treatment of overactive bladder. Fig. (1) . Role of -adrenoceptor (AR) subtypes in the lower urinary tract.
